Edward M. Kaye M.D.
CEO at Stoke Therapeutics Inc.
Sits on 2 boards. Last updated September 27, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Cytokinetics Incorporated, 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Cytokinetics Incorporated May 27, 202697.0%
-
Stoke Therapeutics Inc. June 3, 202587.4%
-
Cytokinetics Incorporated May 10, 202362.1%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 18, 2026 | Stoke Therapeutics Inc. | Open-market sale | −11,930 | $32.01 | $381,846 |
| Aug 18, 2026 | Stoke Therapeutics Inc. | Open-market sale | −637 | $32.47 | $20,682 |
| Aug 14, 2026 | Stoke Therapeutics Inc. | Option exercise | +26,250 | — | — |
| Jul 15, 2026 | Cytokinetics Incorporated | Grant or award | +151 | $82.62 | $12,476 |
| Jun 1, 2026 | Cytokinetics Incorporated | Open-market sale | −2,933 | $76.09 | $223,172 |
| May 27, 2026 | Cytokinetics Incorporated | Grant or award | +2,851 | — | — |
| Apr 15, 2026 | Cytokinetics Incorporated | Grant or award | +191 | $65.37 | $12,486 |
| Mar 15, 2026 | Stoke Therapeutics Inc. | Option exercise | +35,500 | — | — |
| Mar 15, 2026 | Stoke Therapeutics Inc. | Option exercise | +26,250 | — | — |
| Jan 15, 2026 | Cytokinetics Incorporated | Grant or award | +197 | $63.44 | $12,498 |
| Dec 8, 2025 | Stoke Therapeutics Inc. | Open-market sale | −3,825 | $31.44 | $120,258 |
| Dec 8, 2025 | Stoke Therapeutics Inc. | Open-market sale | −8,274 | $32.52 | $269,070 |
| Dec 8, 2025 | Stoke Therapeutics Inc. | Open-market sale | −1,331 | $33.10 | $44,056 |
| Dec 5, 2025 | Stoke Therapeutics Inc. | Open-market sale | −6,367 | $31.33 | $199,478 |
| Dec 5, 2025 | Stoke Therapeutics Inc. | Open-market sale | −1,681 | $31.15 | $52,363 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.